share_log

Recursion Pharmaceuticals | 424B5: Prospectus

Recursion Pharmaceuticals | 424B5: Prospectus

Recursion Pharmaceuticals | 424B5：募資說明書
美股SEC公告 ·  06/28 01:08
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. (Recursion) has announced the offering of 30,769,230 shares of its Class A common stock at a public offering price of $6.50 per share. The offering is filed under Rule 424(b)(5) with the Securities and Exchange Commission (SEC) and is detailed in the prospectus supplement dated June 26, 2024. The shares are listed on the Nasdaq Global Select Market under the symbol 'RXRX.' The last reported sale price of Recursion's Class A Common Stock on Nasdaq was $8.76 per share as of June 26, 2024. The underwriters for the offering are Goldman Sachs & Co. LLC, J.P. Morgan, and Allen & Company LLC, who have the option to purchase an additional 4,615,384 shares. The offering is expected to close on or about June 28, 2024. The net proceeds from the offering, estimated at approximately $188.9 million before expenses, are intended for the advancement of Recursion's preclinical and clinical programs, platform technologies, and for general corporate purposes, including potential strategic investments and acquisitions.
Recursion Pharmaceuticals, Inc. (Recursion) has announced the offering of 30,769,230 shares of its Class A common stock at a public offering price of $6.50 per share. The offering is filed under Rule 424(b)(5) with the Securities and Exchange Commission (SEC) and is detailed in the prospectus supplement dated June 26, 2024. The shares are listed on the Nasdaq Global Select Market under the symbol 'RXRX.' The last reported sale price of Recursion's Class A Common Stock on Nasdaq was $8.76 per share as of June 26, 2024. The underwriters for the offering are Goldman Sachs & Co. LLC, J.P. Morgan, and Allen & Company LLC, who have the option to purchase an additional 4,615,384 shares. The offering is expected to close on or about June 28, 2024. The net proceeds from the offering, estimated at approximately $188.9 million before expenses, are intended for the advancement of Recursion's preclinical and clinical programs, platform technologies, and for general corporate purposes, including potential strategic investments and acquisitions.
Recursion Pharmaceuticals, Inc.（Recursion）宣佈以每股6.50美元的公開發行價格公開發行30,769,230股A類普通股。該發行根據424（b）（5）規則向證券交易委員會（SEC）報告，並詳細說明在2024年6月26日的招股說明書補充中。這些股票在納斯達克全球精選市場上以"RXRX"標誌列出。截至2024年6月26日，Recursion的A類普通股在納斯達克的最後報價爲每股8.76美元。發行商是高盛，J.P. Morgan和Allen & Company LLC，其有購買另外4,615,384股股票的選擇。發行預計於2024年6月28日或前後結束。擬募集資金約爲1.889億美元（扣除費用），用於推進Recursion的臨床前和臨床計劃，平台技術以及用於一般公司用途，包括潛在的戰略投資和收購。
Recursion Pharmaceuticals, Inc.（Recursion）宣佈以每股6.50美元的公開發行價格公開發行30,769,230股A類普通股。該發行根據424（b）（5）規則向證券交易委員會（SEC）報告，並詳細說明在2024年6月26日的招股說明書補充中。這些股票在納斯達克全球精選市場上以"RXRX"標誌列出。截至2024年6月26日，Recursion的A類普通股在納斯達克的最後報價爲每股8.76美元。發行商是高盛，J.P. Morgan和Allen & Company LLC，其有購買另外4,615,384股股票的選擇。發行預計於2024年6月28日或前後結束。擬募集資金約爲1.889億美元（扣除費用），用於推進Recursion的臨床前和臨床計劃，平台技術以及用於一般公司用途，包括潛在的戰略投資和收購。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。